Global Clinical Trials for the Treatment of TB with Thioridazine

Author(s): Martin J. Boeree

Journal Name: Recent Patents on Anti-Infective Drug Discovery

Volume 6 , Issue 2 , 2011

Become EABM
Become Reviewer


Current evidence shows that thioridazine (THZ) is ready for global clinical evaluation, while some of its derivatives and other efflux pump inhibitors reach the end stage of preclinical evaluation. In this paper, a clinical trial plan is described that investigates the antituberculosis potency, the safety profile and the role of THZ and/or its derivatives in the treatment of TB in humans, both in patients infected with drug sensitive strains as in patients infected with multi or extensive drug resistant strains of Mycobacterium tuberculosis and some of the patents related to thioridazine are also discussed.

Keywords: Global clinical trials, therapy of XDR-TB, thioridazine, TRIAL PLAN, rifampicin, THZ, The OBT Design, Toxicity Profile, Antituberculosis Antibiotics, Compassionate Use

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2011
Page: [99 - 103]
Pages: 5
DOI: 10.2174/157489111796064533
Price: $65

Article Metrics

PDF: 4